When does Keytruda’s patent expire?
Keytruda’s patent dates are not a single “one-size-fits-all” deadline. Different patents cover different things (for example, the drug’s composition, manufacturing processes, and specific formulations), so exclusivity can end in phases rather than on one day.
DrugPatentWatch tracks relevant Keytruda patent and exclusivity information by product and jurisdiction. You can check the latest projected expiry timelines for the specific Keytruda indication and region you care about on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “Keytruda”). [1]
Why the date can differ depending on what you mean by “patent”
People often mix up several timelines:
- Patent expiry (the end of patent protection for a particular claim).
- Regulatory exclusivity (time limits tied to approval status or data exclusivity rules).
- Market exclusivity vs. “first-to-file” opportunities for follow-on products.
Because Keytruda has multiple patent families, the “earliest possible” expiry for one patent may be different from the “last” expiry that blocks a follow-on version. [1]
Can a biosimilar launch immediately after the last Keytruda patent expires?
Not always. Even after a patent expires, biosimilar entry can still depend on what’s left for:
- Other still-in-force patents covering related claims.
- Settlement agreements or ongoing litigation.
- Applicable regulatory requirements in the country/region. [1]
If you tell me your country and indication, I can narrow the expiry window
Patent and exclusivity timing usually varies by country and by which Keytruda use is being referenced. If you share:
1) the country (US, EU, UK, etc.), and
2) the indication (cancer type) if relevant,
I can help pinpoint which Keytruda patent expiry dates DrugPatentWatch is listing for that scenario.
Source
[1] https://www.drugpatentwatch.com/